Biogen (NASDAQ:BIIB – Get Free Report) had its price target decreased by research analysts at The Goldman Sachs Group from $281.00 to $245.00 in a research note issued to investors on ...

More stable investment management and net interest income could cause investors to reassess Goldman's earnings quality and increase their willingness to pay a premium for it.

Goldman Sachs CEO David Solomon was awarded an $80 million stock bonus to stay at the helm for another five years, a stark turnaround for a leader whose survival was questioned after the firm's ...